Editas Medicine, Inc. (LON:0IFK)

Editas Medicine Statistics

Total Valuation

Editas Medicine has a market cap or net worth of GBP 126.64 million. The enterprise value is 19.63 million.

Market Cap	126.64M
Enterprise Value	19.63M

Important Dates

The next estimated earnings date is Thursday, March 5, 2026.

Earnings Date	Mar 5, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	97.62M
Shares Outstanding	n/a
Shares Change (YoY)	+3.57%
Shares Change (QoQ)	+6.73%
Owned by Insiders (%)	0.36%
Owned by Institutions (%)	47.92%
Float	97.26M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.67
PB Ratio	12.65
P/TBV Ratio	12.65
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-0.13
EV / Sales	0.58
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.15

Financial Position

The company has a current ratio of 2.86, with a Debt / Equity ratio of 1.46.

Current Ratio	2.86
Quick Ratio	2.81
Debt / Equity	1.46
Debt / EBITDA	n/a
Debt / FCF	-0.11
Interest Coverage	-18.04

Financial Efficiency

Return on equity (ROE) is -211.37% and return on invested capital (ROIC) is -60.51%.

Return on Equity (ROE)	-211.37%
Return on Assets (ROA)	-28.26%
Return on Invested Capital (ROIC)	-60.51%
Return on Capital Employed (ROCE)	-85.50%
Weighted Average Cost of Capital (WACC)	17.24%
Revenue Per Employee	140,269
Profits Per Employee	-604,330
Employee Count	246
Asset Turnover	0.18
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +46.15% in the last 52 weeks. The beta is 2.16, so Editas Medicine's price volatility has been higher than the market average.

Beta (5Y)	2.16
52-Week Price Change	+46.15%
50-Day Moving Average	2.16
200-Day Moving Average	2.50
Relative Strength Index (RSI)	34.33
Average Volume (20 Days)	10,520

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	6.64

Income Statement

In the last 12 months, Editas Medicine had revenue of GBP 34.51 million and -148.67 million in losses. Loss per share was -1.75.

Revenue	34.51M
Gross Profit	-48.19M
Operating Income	-89.04M
Pretax Income	-148.67M
Net Income	-148.67M
EBITDA	-83.35M
EBIT	-89.04M
Loss Per Share	-1.75

Balance Sheet

The company has 123.23 million in cash and 14.62 million in debt, with a net cash position of 108.61 million.

Cash & Cash Equivalents	123.23M
Total Debt	14.62M
Net Cash	108.61M
Net Cash Per Share	n/a
Equity (Book Value)	10.01M
Book Value Per Share	0.11
Working Capital	85.64M

Cash Flow

In the last 12 months, operating cash flow was -133.62 million and capital expenditures -808,663, giving a free cash flow of -134.43 million.

Operating Cash Flow	-133.62M
Capital Expenditures	-808,663
Free Cash Flow	-134.43M
FCF Per Share	n/a

Margins

Gross Margin	-139.66%
Operating Margin	-258.03%
Pretax Margin	-430.84%
Profit Margin	n/a
EBITDA Margin	-241.55%
EBIT Margin	-258.03%
FCF Margin	n/a

Dividends & Yields

Editas Medicine does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.57%
Shareholder Yield	-3.57%
Earnings Yield	-117.39%
FCF Yield	-106.16%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Editas Medicine has an Altman Z-Score of -11.73 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-11.73
Piotroski F-Score	3